ReviewPsychopharmacology2026
Corticosteroid-Induced neuropsychiatric manifestations: From pathophysiology to management.
Review in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corticosteroids are among the most widely prescribed medications in modern medicine, valued for their potent anti-inflammatory and immunosuppressive properties. Despite their therapeutic benefits, corticosteroids are frequently associated with adverse neuropsychiatric manifestations that range from mild mood disturbances to severe psychosis. These side effects, although often under recognized, can significantly impair quality of life and complicate clinical management. The incidence of steroid-induced psychiatric symptoms varies widely, from 5 to 20%, depending on dosage, duration of therapy, and patient vulnerability. The underlying mechanisms involve dysregulation of the hypothalamicpituitary-adrenal (HPA) axis, alterations in neurotransmitter systems, neuroinflammation, and structural changes in brain regions such as the hippocampus, amygdala, and prefrontal cortex. Clinically, corticosteroid-induced neuropsychiatric effects manifest across a spectrum, including depression, mania, anxiety, psychosis, cognitive deficits, and behavioral disturbances. Risk factors such as high cumulative dose, rapid administration, older age, female sex, and pre-existing psychiatric illness increase susceptibility. Timely recognition and differentiation from primary psychiatric disorders are crucial for effective intervention. Management strategies encompass pharmacological approaches such as dose reduction, antipsychotics, antidepressants, and mood stabilizers, as well as non-pharmacological interventions including psychotherapy, lifestyle modification, and preventive monitoring protocols. This review synthesizes current evidence on the pathophysiology, clinical spectrum, risk factors, diagnostic considerations, and management of corticosteroid-induced neuropsychiatric manifestations. It also highlights research gaps and future directions aimed at mitigating these complications while preserving the therapeutic utility of corticosteroids. Understanding this complex interplay between corticosteroid therapy and neuropsychiatric health is essential for clinicians to optimize patient outcomes.
Indexed as
Identifiers
42132956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.